Objective 3: - Psoriasis patients with metabolic syndrome chosen were devided into 2 groups: 15 Treatment group: 33 psoriasis vulgaris patients with metabolic syndrome were treated by metformin + methotrexate, and Control group: 33 psoriasis vulgaris patients with metabolic syndrome were treated by methotrexate only.